226 related articles for article (PubMed ID: 20503149)
41. Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy.
Li S; Cao J; Xiao N; Cai F
J Child Neurol; 2010 May; 25(5):609-13. PubMed ID: 19779208
[TBL] [Abstract][Full Text] [Related]
42. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy.
Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I
Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453
[TBL] [Abstract][Full Text] [Related]
43. Levetiracetam in tardive dyskinesia.
Meco G; Fabrizio E; Epifanio A; Morgante F; Valente M; Vanacore N; Di Rosa AE; Morgante L
Clin Neuropharmacol; 2006; 29(5):265-8. PubMed ID: 16960471
[TBL] [Abstract][Full Text] [Related]
44. Levetiracetam prophylaxis in pediatric migraine--an open-label study.
Pakalnis A; Kring D; Meier L
Headache; 2007 Mar; 47(3):427-30. PubMed ID: 17371359
[TBL] [Abstract][Full Text] [Related]
45. Out-patient alcohol detoxification--outcome after 2 months.
Klijnsma MP; Cameron ML; Burns TP; McGuigan SM
Alcohol Alcohol; 1995 Sep; 30(5):669-73. PubMed ID: 8554652
[TBL] [Abstract][Full Text] [Related]
46. Levetiracetam for phasic spasticity in multiple sclerosis.
Hawker K; Frohman E; Racke M
Arch Neurol; 2003 Dec; 60(12):1772-4. PubMed ID: 14676055
[TBL] [Abstract][Full Text] [Related]
47. [The relationship between self-efficacy and abstinence from alcohol after outpatient and inpatient treatment--a two year follow-up].
Zingg C; Schmidt P; Küfner H; Kolb W; Zemlin U; Soyka M
Psychother Psychosom Med Psychol; 2009 Aug; 59(8):307-13. PubMed ID: 18792880
[TBL] [Abstract][Full Text] [Related]
48. Levetiracetam intravenous infusion as an alternative to oral dosing in patients with partial-onset seizures.
Baulac M; Brodie MJ; Elger CE; Krakow K; Stockis A; Meyvisch P; Falter U
Epilepsia; 2007 Mar; 48(3):589-92. PubMed ID: 17326794
[TBL] [Abstract][Full Text] [Related]
49. Outpatient treatment of severe peripheral ischemia with intravenous intermittent low-dose iloprost. An open pilot study.
Banyai S; Jenelten R; Wagner S; Allmann J; Banyai M; Koppensteiner R
Int Angiol; 2002 Mar; 21(1):36-43. PubMed ID: 11941272
[TBL] [Abstract][Full Text] [Related]
50. Mirtazapine improves alcohol detoxification.
Liappas J; Paparrigopoulos T; Malitas P; Tzavellas E; Christodoulou G
J Psychopharmacol; 2004 Mar; 18(1):88-93. PubMed ID: 15107190
[TBL] [Abstract][Full Text] [Related]
51. Levetiracetam is not effective for essential tremor.
Elble RJ; Lyons KE; Pahwa R
Clin Neuropharmacol; 2007; 30(6):350-6. PubMed ID: 18090460
[TBL] [Abstract][Full Text] [Related]
52. Pregabalin in outpatient detoxification of subjects with mild-to-moderate alcohol withdrawal syndrome.
Di Nicola M; Martinotti G; Tedeschi D; Frustaci A; Mazza M; Sarchiapone M; Pozzi G; Bria P; Janiri L
Hum Psychopharmacol; 2010 Apr; 25(3):268-75. PubMed ID: 20373479
[TBL] [Abstract][Full Text] [Related]
53. Levetiracetam as adjunctive therapy for acute alcohol withdrawal syndrome in hospitalized patients.
Youland KM; Miller RF; Mahoney LJ; Borgert AJ; Gundrum JD
J Clin Psychopharmacol; 2014 Dec; 34(6):704-8. PubMed ID: 25144138
[TBL] [Abstract][Full Text] [Related]
54. Alcohol withdrawal syndrome: symptom-triggered versus fixed-schedule treatment in an outpatient setting.
Elholm B; Larsen K; Hornnes N; Zierau F; Becker U
Alcohol Alcohol; 2011; 46(3):318-23. PubMed ID: 21414950
[TBL] [Abstract][Full Text] [Related]
55. An open pilot study of tiagabine in alcohol dependence: tolerability and clinical effects.
Paparrigopoulos T; Tzavellas E; Karaiskos D; Malitas P; Liappas I
J Psychopharmacol; 2010 Sep; 24(9):1375-80. PubMed ID: 19346278
[TBL] [Abstract][Full Text] [Related]
56. Voluntary alcohol consumption and plasma beta-endorphin levels in alcohol preferring rats chronically treated with levetiracetam: a preliminary study.
Zalewska-Kaszubska J; Bajer B; Czarnecka E; Dyr W; Gorska D
Physiol Behav; 2011 Mar; 102(5):538-41. PubMed ID: 21187108
[TBL] [Abstract][Full Text] [Related]
57. Levetiracetam in the treatment of alcohol dependence: toward the end of the story?
Le Strat Y
Alcohol Clin Exp Res; 2012 Aug; 36(8):1309-10. PubMed ID: 22823576
[TBL] [Abstract][Full Text] [Related]
58. An observational trial to investigate the efficacy and tolerability of levetiracetam in trigeminal neuralgia.
Mitsikostas DD; Pantes GV; Avramidis TG; Karageorgiou KE; Gatzonis SD; Stathis PG; Fili VA; Siatouni AD; Vikelis M
Headache; 2010 Sep; 50(8):1371-7. PubMed ID: 21044281
[TBL] [Abstract][Full Text] [Related]
59. Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose study.
Papp LA
J Clin Psychiatry; 2006 Oct; 67(10):1573-6. PubMed ID: 17107249
[TBL] [Abstract][Full Text] [Related]
60. A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients.
Fertig JB; Ryan ML; Falk DE; Litten RZ; Mattson ME; Ransom J; Rickman WJ; Scott C; Ciraulo D; Green AI; Tiouririne NA; Johnson B; Pettinati H; Strain EC; Devine E; Brunette MF; Kampman K; A Tompkins D; Stout R;
Alcohol Clin Exp Res; 2012 Aug; 36(8):1421-30. PubMed ID: 22324516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
